Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Presurgical pazopanib for renal cell carcinoma with inferior vena cava tumor thrombus
ChiCTR-OPB-17013321Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pazopanib in renal cell carcinoma (RCC), sponsored by Chinese PLA General Hospital. Primary endpoint: Thrombus down-staging rate. Started Nov 2017; status: recruiting.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR-OPB-17013321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPB-17013321.